Efficacy of inhaled nitric oxide in preterm infants ≤ 34 weeks: a systematic review and meta—analysis of randomized controlled trials
Wirksamkeit von inhaliertem Stickstoffmonoxid bei Frühgeborenen ≤34 Wochen: systematische Übersichtsarbeit und Metaanalyse randomisierter kontrollierter Studien
Frontiers in Pharmacology · 11.01.2024 · 14
DOI: 10.3389/fphar.2023.1268795 ↗Auf einen Blick
Bei Frühgeborenen ≤34 Wochen war inhalatives Stickstoffmonoxid mit weniger bronchopulmonaler Dysplasie verbunden. Auch der kombinierte Endpunkt aus Tod oder BPD war reduziert.
Fragestellung
Wie wirksam und sicher ist inhalatives Stickstoffmonoxid bei Frühgeborenen ≤34 Wochen?
Methode
Systematische Übersichtsarbeit und Metaanalyse randomisierter kontrollierter Studien; Suche in PubMed, Embase und Cochrane Library bis 1. Juni 2023; Bewertung mit GRADE.
Ergebnisse
17 Studien mit 4.080 Neugeborenen und 7 Follow-up-Studien. BPD: RR 0,92 (95 %-KI 0,86–0,98). Tod oder BPD: RR 0,94 (95 %-KI 0,90–0,98). Keine Zunahme neurologischer oder anderer neonataler Komplikationen.
Einschränkungen
Subgruppenanalyse zeigte Effekte nur unter bestimmten Bedingungen; weitere Daten für eine Zulassung in dieser Patientengruppe erforderlich.
Schlussfolgerung der Autor:innen
Inhalatives NO verringerte die BPD-Inzidenz bei Neugeborenen in der 36. SSW; der Effekt hing von Alter, Geburtsgewicht, Dosis und Dauer ab. Es könnte eine vielversprechende Prävention für BPD sein.
Kernaussagen
- BPD seltener unter iNO: RR 0,92 (95 %-KI 0,86–0,98)
- Tod oder BPD reduziert: RR 0,94 (95 %-KI 0,90–0,98)
- Kein Anstieg kurzer oder langfristiger neurologischer Risiken
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.01.2024. Verfasst von Zhoushan Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Guangzhou Key Laboratory of Neonatal Intestinal Diseases, The Third Affiliated Hospital of Guangzhou Medical University, G…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Neonatologie
Abstract (Originalsprache)
Background
The effect of inhaled nitric oxide (iNO) in neonates >34 weeks on improving respiration is well documented. However, the efficacy of iNO in preterm infants ≤34 weeks remains controversial.
Objectives
The main purpose of this review is to assess the effectiveness and safety of iNO treatment in preterm infants ≤34 weeks. Search methods: We systematically searched PubMed, Embase and Cochrane Libraries from their inception to 1 June 2023. We also reviewed the reference lists of retrieved studies. Selection criteria: Our study involved randomized controlled trials on preterm infants ≤34 weeks, especially those receiving iNO treatment, and mainly assessed outcomes such as bronchopulmonary dysplasia (BPD) and mortality. Two authors independently reviewed these trials, extracted data, and evaluated study biases. Disagreements were resolved by consensus. We used the GRADE method to assess evidence quality.
Results
Our research included a total of 17 studies involving 4,080 neonates and 7 follow-up studies. The synthesis of results showed that in neonates, iNO treatment reduced the incidence of BPD (RR: 0.92; 95% CI: 0.86–0.98). It also decreased the composite outcome of death or BPD (RR: 0.94; 95% CI: 0.90–0.98), without increasing the risk of short-term (such as intraventricular hemorrhage, periventricular leukomalacia) and long-term neurological outcomes (including Bayley mental developmental index <70, cerebral palsy and neurodevelopmental impairment). Furthermore, iNO did not significantly affect other neonatal complications like sepsis, pulmonary hemorrhage, necrotizing enterocolitis, and symptomatic patent ductus arteriosus. Subgroup analysis revealed that iNO significantly reduced BPD incidence in neonates at 36 weeks under specific intervention conditions, including age less than 3 days, birth weight over 1,000 g, iNO dose of 10 ppm or higher, or treatment duration exceeding 7 days ( p < 0.05).
Conclusion
Inhaled NO reduced the incidence of BPD in neonates at 36 weeks of gestation, and the effect of the treatment depended on neonatal age, birth weight, duration and dose of iNO. Therefore, iNO can be considered a promising treatment for the potential prevention of BPD in premature infants. More data, however, would be needed to support nitric oxide registration in this specific patient population, to minimize its off-label use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neonatology, Guangzhou Key Laboratory of Neonatal Intestinal Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Ba…
- Department of Obstetrics and Gynecology, School of Medicine, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China.
Zitieren
APA
Feng, Z., Wu, X., Xu, X., Cui, Q., & Wu, F. (2024). Efficacy of inhaled nitric oxide in preterm infants ≤ 34 weeks: a systematic review and meta—analysis of randomized controlled trials. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1268795
Vancouver
Feng Z, Wu X, Xu X, Cui Q, Wu F. Efficacy of inhaled nitric oxide in preterm infants ≤ 34 weeks: a systematic review and meta—analysis of randomized controlled trials. Frontiers in Pharmacology. 2024;14. doi:10.3389/fphar.2023.1268795
BibTeX
@article{Feng2024,
author = {Feng, Zhoushan and Wu, Xiaohong and Xu, Xiaona and Cui, Qiliang and Wu, Fan},
title = {Efficacy of inhaled nitric oxide in preterm infants ≤ 34 weeks: a systematic review and meta—analysis of randomized controlled trials},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {14},
doi = {10.3389/fphar.2023.1268795}
}
EUVIMED